Evolus opened lower at $7.38, compared with its previous close of $7.42. In the last trading session, the stock traded between $7.15 and $7.65. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Evolus is now worth
$ 99.01
Resulting in a loss of
$ 0.99 (0.99%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.23 (-3.13%)
Day High
$7.65
Day Low
$7.15
Day Open
$7.38
Prev Close
$7.42
Volume
5,88,994
1W Return
-3.80%
1M Return
-7.18%
3M Return
-13.85%
6M Return
13.73%
1Y Return
2.83%
Market Cap ($ Mn)
476
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-20.89%
EPS (TTM)
$-0.19
1 Week
-3.80%
1 Month
-7.18%
3 Months
-13.85%
6 Months
13.73%
9 Months
67.16%
BTIG maintains Buy on Evolus, raises price target to $15
BTIG maintained a Buy rating on Evolus. Price target raised from $13 to $15. Analyst Sam Eiber issued the rating update.
7 days agoEvolus Q3FY26 Results: Revenue up 13% to $78M, fourth straight quarter of positive EBITDA
Revenue rose 13% YoY to $78 million in Q3FY26. Adjusted EBITDA turned positive for the fourth consecutive quarter at $1.2 million. Hyaluronic acid segment grew nearly 40% in the quarter. Full-year revenue guidance reaffirmed at $330-337 million.
8 days agoPomerantz investigates Evolus after FDA warning triggers stock decline
Pomerantz LLP is investigating Evolus for potential securities fraud following an FDA warning letter. The FDA flagged an Instagram promotion for Jeuveau as false or misleading on October 2, 2026. Evolus stock fell $0.55 per share, or 7.15%, to close at $7.14 on the day of disclosure. The FDA objected to claims that Jeuveau could make frown lines completely "gone" and work in two days.
9 days agoPomerantz probes Evolus following FDA warning on Jeuveau ads
Pomerantz LLP investigates Evolus for potential securities fraud following an FDA warning letter. The FDA flagged an Instagram ad for Jeuveau as misleading for minimizing safety warnings. Evolus shares fell 7.15% to $7.14 on October 2, 2026, after the disclosure. The warning cited claims that Jeuveau could make frown lines completely "gone".
23 days agoEvolus faces securities probe after FDA warning letter hits stock
Schall, Brown & Schwartz LLP is investigating Evolus, Inc. for securities law violations. FDA issued a warning letter flagging Jeuveau's Instagram promotion as misleading. Evolus shares fell 7.15% on October 2, 2026, following the FDA disclosure. The FDA cited minimized safety information and claims of "complete results".
1mo agoFDA warns Evolus over misleading Jeuveau social media claims
FDA issued a warning letter to Evolus Inc regarding misleading Instagram promotions for Jeuveau. Regulators cited exaggerated efficacy claims and downplayed safety risks in social media reels. Company has 15 working days to submit a compliance plan or cease distribution of violative materials. Evolus shares fell 5.92% to $7.23 following the disclosure.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Evolus is now worth
$ 99.01
Resulting in a loss of
$ 0.99 (0.99%)
Note: Past profits do not guarantee future returns.
